Value in Health

Article	Citations
Author Reply	86
When Do Value-Based Contracts Add Value? Insights From Probabilistic Simulations	86
CO107 Assessing Short and Long-Term Outcomes in Drug-Associated Acute Kidney Injury	82
EE52 The Burden of Intravenous vs Subcutaneous Oncological Products Application in Honduras	76
CO67 Network Meta-Analysis to Compare the Efficacy Between Different Classes of PCSK9 Inhibitors, siRNA Vs. PCSK9 mAb, in Asian Patients With Hypercholesterolemia at Increased Cardiovascular Risk	74
EPH156 Multimorbidity and Its Associations with Adverse Cardiovascular Events and Healthcare Costs Among Patients with Atherosclerotic Cardiovascular Disease: A Real-World Evidence Study	72
EE181 Impact of Type 1 Diabetes on Productivity and Out-of-Pocket Costs of Adult Continuous Glucose Monitoring Users in the United States: Results From a Cross-Sectional Survey in the United States	70
EE105 Cost-Effectiveness Analysis of Linperlisib for Relapsed or Refractory Follicular Lymphoma Based on Matching Adjusted Indirect Comparison in China	66
EE266 The Economics Promises of a Cure: Best Practices to Guide Economic Negotiations for the Reimbursement of Curative Therapies for Cancer	62
EE310 The Burden of Blood Transfusions Associated With Lower-Risk Myelodysplastic Syndromes (LR-MDS): Findings From a Survey of Health Care Professionals (HCPs) in Brazil, Germany, and Japan	60
EPH175 Assessment of Streptococcus Pneumoniae as Cause of Acute Otitis Media in Young Children in Colombia: A Prospective Study	58
EE311 Exploring Environmental Impacts of Switching Salmeterol/Fluticasone Propionate (SAL/FP) from Metered Dose Inhaler (MDI) to Dry Powder Inhaler (DPI) in Respiratory Illness in the United Kingdom	56
EE106 Cost-Effectiveness Analysis of Belimumab for the Treatment of Adults With Active Lupus Nephritis in China	53
EPH190 Trends and Disparities in Perinatal Health Outcomes Among Women from Refugee Backgrounds in Victoria, Australia: A Population-Based Study	51
EE79 Real-World Clinical and Economic Burden of Primary Biliary Cholangitis in the United States	50
EE258 Cost-Effectiveness of Transcatheter Aortic Valve Implantation (TAVI) for High-Risk Patients in Chile	49
EE226 Productivity Loss Among Persons With Multiple Sclerosis Treated With Ocrelizumab Vs Other Disease-Modifying Therapies	48
EPH115 Sex Differences on Limitations in Physical Functioning and Overall Quality of Life of People Living with Myasthenia Gravis from the MGFA Global MG Patient Registry (MGFAPR) in the US	45
HSD25 Patients’ Rare Disease Diagnoses and Their Impact on Physicians’ Emotions: A Cross-Sectional Study in the United States	44
HPR38 Estimating the Outcome Disparities in BIPOC and Economically-Disadvantages Patients With Systemic Lupus Erythematosus (SLE)	41
EPH27 The Efficacy of Interventions Utilized in Communicating Risk Information to Improve Behavioral Outcomes Among Individuals Who Are Genetically Predisposed of Type 2 Diabetes: A Systematic Review	41
RWD135 Right-Sided vs Left-Sided Colorectal Cancer Hospitalization Outcomes in the US	40
PCR222 Comparison of Recanalisation Therapies in Terms of Quality of Life in Ischaemic Stroke Patients in Hungary	40
PCR207 Health-Related Quality of Life and Its Associate Factors Among Residents in Tianjin, China: Findings from 2023 National Health Service Survey	38
CO210 An Updated Systematic Review and Network Meta-Analysis on Risks of Respiratory Tract Infections with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis	38

SA48 Methods to Account for the Impact of COVID-19 in Real-World Retrospective Studies of Economic Outcomes: A Targeted Literature Review	37
PT4 Will the IRA's Negotiation Timelines Delay Access to Drugs for Orphan Indications?	37
EPH222 Trends of Mortality Related With Dengue in Colombia 2012-2021	37
EE481 Long-Term Cost-Effectiveness of Tirzepatide Versus Placebo for Individuals With Type 2 Diabetes and Obesity	36
SA13 Approaches to Electronic Health Records Notes Selection: Considerations for Best Practices	36
P7 Costs and Health Care Resource Utilization Associated with Negative Symptoms Among Patients with Schizophrenia in the United States	36
CO18 Impact of Empiric Treatment Failure on Healthcare Resource Utilization and Costs Among Females With Uncomplicated Urinary Tract Infections in a US-Based Integrated Health Delivery Network	35
P53 Validation of AI-Generated Synthetic Data for Outcomes Research: A Clinico-Genomics Case Study	35
CO49 Progression of Chronic Kidney Disease Among Older Adults with Hypertension Using Group-Based Trajectory Modeling	34
CO72 Investigating Regional Differences in Cardiovascular Outcomes Among Patients Diagnosed with Hypertrophic Cardiomyopathy	33
EE45 Influential Factors on the Economic Justifiable Price: Systematic Investigation of Factors and Mechanisms Beyond the Incremental Cost Effectiveness Ratio	32
EE438 A Budget Impact Model (BIM) for the Introduction of the TEARCARE® System to a United States (US) Health Plan for the Treatment of Meibomian Gland Dysfunction (MGD)-Associated Dry Eye Disease (DE	31
EE426 Cost-Comparison Analysis of Non-Invasive Testing Strategies for Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Veteran Population	31
RWD50 Progression-Free Survival after First-Line Treatment in Endometrial Cancer Patients: A Real-World Perspective from Brazil and Argentina	30
EPH14 Association between the Use of Macrolide Antibiotics and Recurrent Wheezing in Hospitalized Infants with Bronchiolitis	30
PCR52 Early Real-World Experience With Abrilada Within the Canadian Patient Population	30
HPR144 Optimization in Universal Health Coverage Design in South Africa Considering Both Health Outcomes and Health-Induced Poverty Outcomes	29
OP17 Are Dengue-Related Technological Solutions Evolving to Address the Global Public Health Problem?	29
SA76 A Targeted Literature Review of Economic Evaluations, Health-Related Quality of Life, Healthcare Resource Use, and Costs Associated With Polymyalgia Rheumatica	29
MT14 Assessing the Association Between Cardiovascular Acoustic Biomarkers and Heart Failure: A Systematic Literature Review	29
HTA56 ICER Vs NICE – What Are Your Key Considerations for Health Technology Assessments for Rare Disease Therapies? Insights from a Review of Completed Assessments (2017-PRESENT)	28
MSR45 Development and Validation of Machine Learning Algorithms to Predict 1-Year Ischemic Stroke and Bleeding Events in Patients With Atrial Fibrillation and Cancer	28
EPH211 Treatment Patterns and Clinical Characteristics of Patients Diagnosed with Metastatic NSCLC in Hmo from Colombia: A Real Word Evidence Study	28
RWD141 Assessing the Potential Value of the Flatiron Health Commercial Mortality Data Combined with Publicly Available Death Data for Non-Oncology Research	27
SA11 Real-World Effectiveness and Safety of First-Line Pembrolizumab Monotherapy for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis	27
Editorial Board	27
MSR65 The Benefits of a Complex Identification and Stratification Model for Depression: Insights from a Large Claims Analysis Study	27
EPH282 3-Year Healthcare Resource Consumptions of Patients With Immunoglobulin A Nephropathy in a Large Real-World Italian Database	26
CO146 Systematic Literature Review of Hospital Time and Resource Consumption in Subcutaneous and Intravenous Oncologic Biologic Therapies: The Case Study of Atezolizumab From an Italian Perspective	26
HPR97 More Public Funding? A Choice Experiment on the Healthcare Funding System for Older Populations	26
PCR237 Patient Activation and Health Outcomes in Spinal Surgery: A Systematic Literature Review of Measures, Effects, and Strategies	26
HPR215 Exploring the Efficacy, Safety, and Regulatory Approval of Priority Reviewed Innovative Drugs in China (2015-2023)	26
HTA75 Payer Perceptions of Health Inequalities in Reimbursement Decision-Making: Results of a Global Survey	25
EE278 A Survey on Japanese Drug Pricing and Treatment Costs of Cancer Chemotherapy Drugs: The Case of Monoclonal Antibodies	25
MSR165 Evaluating the Effectiveness of AI-Generated vs Real Abstracts in Training Machine Learning Models for Study Selection in Systematic Literature Reviews	25
PCR147 Treatment Preferences of Patients With Crohn's Disease in Greece: A Cross-Sectional Patient Survey	25
EE249 The Hidden Burden of Migraine: Analysis Using a Fiscal Framework in Colombia	24
PCR80 Barriers and Facilitators to the Recruitment and Engagement of Diverse Populations Into Patient Engagement Groups: A Scoping Review	24
HTA170 Use of Off-Label Comparators in Health Technonology Assessment in Portugal: A Review of Reimbursement Appraisal Reports	24
HSD125 Patient Pathways and Healthcare Resources Use in Hepatocellular Carcinoma: Full Analyses of the OPAL Study in Portuguese Population	24
P54 An Insight Into Real-World Evidence (RWE) As a Component of Submission to NICE & CADTH in the Last 3 Years	24
CO98 The Impact of Approved Anti-Obesity Medications on the Incidence of Osteoarthritis, Healthcare Resource Use and Costs Among Patients With Obesity: A Retrospective Cohort Study	24
MT60 Artificial Intelligence-Based Tools Designed to Predict Future Mechanical Ventilation and/or Mortality in Hospitalised COVID-19 Patients: A Systematic Literature Review	24
EE198 Healthcare Resource Utilization (HCRU) by Patients With Duchenne Muscular Dystrophy (DMD) Using UK Patient Level Data	23
RWD156 Patterns of Co-Medications Among People With Schizophrenia in Hong Kong	23
PT37 Comparison of ICD-10 Diagnoses and Longitudinal Estimated Glomerular Filtration Rate (eGFR) in the Detection of Incident Stage 3 Chronic Kidney Disease (CKD): A Retrospective Comparison Study Usi	23
HPR87 Poland's Medical Fund Act: Progress of the New Fast-Track TLI Reimbursement Pathway	23
EPH19 Ovarian Cancer Age-Adjusted Mortality Rates in Chile During 2002-2019	23
EPH168 A Descriptive Epidemiological Study of Pediatric Sleep Medications in Japan: A Health Insurance Claims-Based Analysis	23
CO36 Placebo Effect for Clinical Remission in Induction and Maintenance Treatment in Crohn's Disease: A Systematic Literature Review and Meta-Analysis	22

MSR118 Integrating Large Language Models Into an Existing Review Process: Promises and Pitfalls	21
EE375 An Early Health Economic Assessment on a New Method to Estimate 12-Hour Lithium Levels	21
MSR125 AI-Powered Search Strategy Development and Optimization for Systematic Literature Reviews	21
HTA131 Opportunities for Patient Involvement in HTA in the Philippines: Lessons From Guidelines in Europe, North America, and the Asia-Pacific	21
HPR78 Opportunities and Barriers for the Implementation of the Personalized Medicine in Lithuania	20
HTA310 Are Global Health Technology Assessment (HTA) Processes Inclusive and Equitable? A Scoping Review	20
EE724 Healthcare Resources Utilization and Costs of Treatment Associated With Anogenital Warts in South Africa: Public and Private Perspective	20
MSR177 Health-Related Quality-of-Life (HRQoL) Assessment for Japanese Cognitive Impairment Associated With Schizophrenia (CIAS)	20
HTA368 Do We Need to Adapt Our Health Technology Assessment (HTA) Systematic Literature Review (SLR) Methods to Comply With the New Joint Clinical Assessment (JCA) SLR Requirements?	20
EPH249 Epidemiology of Patients With Thymic Carcinoma in the United States: A Systematic Literature Review	20
RWD108 Unveiling the Burden and Impact of Flares in Patients With Moderate-to-Severe Atopic Dermatitis: Results From the Adelphi Real World Disease Specific Program in Europe	20
PCR306 Exploring the Difference That Patient Involvement in HTA Makes in Cancer	20
EE396 Evaluating Long-Term Healthcare Resource Utilization in Biopsy-Confirmed MASLD: A Retrospective Longitudinal Observational Cohort Study in Sweden	20
EPH288 Characteristics of NASH Patients Who Develop Hepatocellular Carcinoma (HCC) With and Without a Corresponding Cirrhosis Diagnosis	20
CO79 Effectiveness of Secukinumab in Patients With Moderate to Severe Hidradenitis Suppurativa: Results From a Meta-Analysis	20
RWD157 A Real-World Study of Multiple Myeloma Patients With at Least 3 Prior Treatment Lines and Triple Class Exposed Disease in Finland: Outcomes and Need for Healthcare Resource Use	19
HTA246 Improving Access to Innovative Therapies for Rare Bleeding Disorders: Evidence From High Income Countries	19
CO142 Systematic Literature Review of Real-World Evidence on Overall Survival in Cancer Patients Before and After the Approval of Anti-PD-(L)1 Therapy	19
HSD9 Development of a Framework for a Networked Service Model for the Care of Adults With Rare Bone Conditions: Healthcare Professional Survey for X-Linked Hypophosphataemia (XLH)	19
EE306 Comparison of Methods for Extrapolation of Drug Survival of Biologics in Psoriasis NICE Submission Cost-Effectiveness Analyses	19
HPR117 The Economic Burden of Lung Cancer in Greece: A Systematic Review of the Literature	19
HTA78 Health Technology Assessment (HTA) Key Drivers for Oral Oncology Products: Comparison Between Brazil and European Countries	19
PCR89 Humanistic Burden of Adrenoleukodystrophy: A Systematic Review	18
PCR174 Importance of Specific Clinical Trial Enrollment Strategies for Native Hawaiian, Pacific Islander, and Asian Patients With Type 2 Diabetes Mellitus	18
HPR225 Impact of the 2021 US Federal X-Waiver Practice Guideline Change on the Prescribing of Buprenorphine and Naltrexone for Treating Opioid Use Disorder in Medicaid Population	18
EE307 Comparing Ancillary Services Associated With Subcutaneous Versus Intravenous Medication Administration	18
PCR39 Health State Utility Values for Patients With Paroxysmal Nocturnal Hemoglobinuria Using EQ-5D-5L	18
HTA308 Analysis of Factors Influencing the Assessment of Metastatic Solid Oncology Products in France: Central Role of Overall Survival (OS) Results and Other Parameters	18
SA95 A Pragmatic Data Extraction Approach for a Systematic Literature Review for Indirect Treatment Comparison Using Single-Arm Real-World Studies	17
MSR61 Investigating the Use of the Difference Method for Sampling More Than Two Ordered Variables	17
MSR111 Using Patient-Level Simulation to Estimate Long-Term Survival in Idiopathic Pulmonary Fibrosis	17
EE830 Exploring Long-Term Durability Assumptions in Cost-Effectiveness Models of Cell and Gene Therapies: A Study of 39 Health Technology Assessments	17
HPR16 Performance Indicators for the Assessment of Ageing-in-Place Reform Policies: A Scoping Review and Evidence Map	17
EE347 Cost-Effectiveness and Value-Based Price of High-Dose Quadrivalent Influenza Vaccine Among Elderly Populations in Taiwan	17
RWD134 Healthcare Pathways and Therapeutic Outcomes of Patients With Spinal Muscular Atrophy: Results From the 12-Year Real-World Study EPI-SMA Based on the French National Healthcare Database (SNDS)	17
SA53 Epidemiology and Hospital Management of Patients With PROS in France	17
HPR15 Innovative Rebate Management in Oncology Drug Budgets: Streamlining Operations and Enhancing Financial Efficiency Through Technology in Newfoundland and Labrador's Cancer Care Program	17
MT2 Real-World Evidence (RWE) in Action: A Review of Australia's Health Technology Assessment (HTA) of Non-Drug Health Technologies	17
HPR185 Performance-Based vs Finance-Based Managed Entry Agreements (MEAs): Global Trends and Challenges	16
PCR277 Patients’ Perspective of the Access to and Quality of Care for Chronic Kidney Disease: Insights From the DISCOVER-CKD Qualitative Study	16
EPH239 Positive Airway Pressure (PAP) Therapy in Obstructive Sleep Apnea (OSA): Modeling of 20 Year Mortality and Hospitalizations	16
EE527 Economic Evaluation of Using Romiplostim for Early Immune Thrombocytopenia in Qatar	16
MSR7 Superdeduper: Testing New AI-Powered System for Deduplicating References in Literature Reviews	16
EE393 Economic Impact of COVID-19 Vaccination Programs on Healthcare Workers: A Comparative Model-Based Analysis in the US, UK, Japan, and the Netherlands	16
EPH9 Influence of Front Nutritional Labeling on Consumer Choices Related to Ultra-Processed Foods: Scoping Review	16
EPH48 Impact of Influenza-like Illness on Health-Related Quality of Life in Japanese Adults	16
EPH80 Impact of the COVID-19 Pandemic on Arterial Hypertension Monitoring and Control in Portugal	16
EPH187 Contextualizing the Impact of Multiple Sclerosis (MS) in England Through HES Analysis	16
PCR192 Quality of Life and Its Drivers for Patients Living With Angelman Syndrome (AS): A Systematic Review	15
MSR105 Tackling Rare Events in Network Meta-Analysis: Comparative Performance of Methods for Sparse Safety Outcomes	15
EE840 Assessing Direct Medical Costs of Stage IV NSCLC in Iraq From Public Payer Perspective	15
EPH147 Situational Analysis of Sexual Health in Cartagena and Bolívar, Colombia 2023	15
SA97 The Relative Effectiveness & Safety of Fluocinolone Acetonide (FAc) and Dexamethasone (DEX) in Diabetic Macular Oedema: A Systematic Review and Matching Adjusted Indirect Treatment Comparison	15
CO81 Pregabalin Utilization and Side Effects Among Hemodialysis Patients Diagnosed With Pruritus or Neuropathic Pain in US Claims Data	15
EE765 The Economic Burden of Mild Cognitive Impairment and Dementia Due to Alzheimer’s Disease in South Korea and Taiwan	15
MSR15 A Novel Crossover Adjustment Analysis of Overall Survival Results From the Phase 3 ClarIDHy Study of Ivosidenib Versus Placebo in Patients With MIDH1 Cholangiocarcinoma	15
Table of Contents	14
Award Winners	14
MSR42 Time to Stop Sinking Resources Into Developing Predictive Models That Yield No Value: A Framework and Opportunities for Health Economic Methods Development to Reduce Waste in Prediction Model De	14
EE504 Leveraging Large Language Models for Conceptualizing Health Economic Models: A Feasibility Study in Oncology	14
HTA86 Indirect Comparisons and Network Meta-Analysis in Spanish Drug Positioning Reports for Price and Financing	14
HPR7 The Discrepancy in Real-World Evidence of New Drug Expenditure Between Actual and Estimated Figures From Manufacturers and Government Agencies in Taiwan	14
HSD79 Physicians’ Experience and Perceptions of Tetrabenazine for the Treatment of Tardive Dyskinesia	14
MSR50 Use of a Fine-Tuned, Clinical, Bidirectional Transformer (BERT) Large Language Model (LLM) to Classify the Patient and Caregiver Voice Through Their Social Media Health Posts: An Example in Non-	14
SA27 A Non-Systematic Review Evaluating Search Strategies Leveraged in HTA Submissions to NICE	14
PT6 An “R-Shiny” Interface Designed As a One-Stop Solution for All Kinds of Survival Analysis According to NICE Technical Support Documents 14 and 21	14
EPH65 Assessment of Enzyme Preparations Consumption in Ukraine in Comparison With Other Countries of the World	13
PCR16 Uncovering the Influence of Smoking on Health Care Processes for Adult Lung Cancer Patients in Chile: Insights From a Multi-Perspective Qualitative Study	13
HTA135 Uncertainty in AMNOG Benefit Assessments: Reflection of G-BA's Underlying Motivation to Cause AbD	13
HTA286 Challenges and Solutions to Estimating Environmental Impact in Health Technology Assessment	13
EE278 Resource Utilization and Caring Cost of People Living With Human Immunodeficiency Virus (PLHIV) in Saudi Arabia: A Tertiary Care University Hospital Experience	13
HTA272 EUnetHTA's HTA Core Model®: A Critical Assessment and Future Outlook	13
PCR62 Treatment Satisfaction and Health-Related Quality of Life in People Living With HIV Receiving DTG/3TC Who Are Treatment Experienced or Treatment Naive in Europe	13
PCR49 A Preliminary Comparison between Analytical Hierarchy Process and Discrete Choice Experiment in Health State Preferences in Hong Kong SAR, China	13
HTA254 Potential Discrepancies/Misalignments in Future EU-HTA Appraisals the POLIVY and Stelara JA3 PICO Example	13
MT36 Use of Mobile Health (MHEALTH) Applications in Cancer: A Trend Analysis	13
EE257 Cost-Effectiveness Analysis of AI-Assisted Radiological Assessment in Patients With Relapsing Remitting Multiple Sclerosis in the UK	13
HTA350 Fixed Effect Versus Random Effects Bayesian Network Meta-Analyses in Practice: What Is Used to Inform National Institute for Health and Care Excellence (NICE) Technology Appraisals?	13
PCR117 A Qualitative Interview Study into the Experiences of Fatigue and Depression in Chronic Hepatitis B	12
HPR218 Recent Advances in Voluntary European Cross-Border Collaborations in Joint HTA and Drug Pricing/Procurement	12

CO21 Matching Adjusted Indirect Comparison (MAIC) of Selpercatinib Vs Cabozantinib in RET Mutation-Positive Advanced Medullary Thyroid Cancer (MTC)	12
PCR76 Generating Health-State Utility Values in Patients Treated with Second-Line Systemic Therapy for Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)	12
RWD100 Comparison of Real-World Safety and Effectiveness of Mepolizumab and Benralizumab in the Management of Severe Asthma: A Systematic Review	12
PCR227 Do Family Spillover Effects of Illness Vary With the Age of the Ill Individual?	12
CO86 Comparing Factors Associated With First and Recurrent Psychiatric Hospitalizations in Adult Patients With Major Depressive Disorder Using Cox Proportional Hazard Model and Extensions	12
PCR122 Psychometric Evaluation of Multiple Sclerosis Impact Scale 29 Version 2 in Relapsing Multiple Sclerosis Patients Participating in a Phase 2 Study of Frexalimab	12
HPR66 Assessing the Impact and Strategic Implications of the HTA Regulation 2021/20282 on National Processes: A Scoping Review and Stakeholders Perspectives Through Semi-Structured Interviews	12
EE85 Health System Costs and Resources for Stage-Specific Breast Cancer: A Population-Based Approach (Updated)	12
HTA62 A Systematic Review of the New NICE Highly Specialised Technologies Criteria: How Do NICE Judge Criteria 3 and 4 to be Met?	12
PCR72 How to Achieve Comprehensive Care for Breast Cancer? Challenges in Chile from the Voice of Patients	12
EE359 Cost-Utility of Bictegravir/Tenofovir Alafenamide/Emtricitabine in Naive Patients over 18 Years of Age Living with Human Immunodeficiency Virus Type 1 Infection, from the Colombian’s Health Syst	11
EPH116 Patient Pathways and Economics of Tumor-Related Hypothalamic Obesity in Germany—A Representative Claims Data Analysis	11
HSD94 Assessing Payer Perspectives on Novel Therapies for the Treatment of Gorlin Syndrome	11
EE372 Descriptive Analysis of Botulinum Toxin Use for Migraine and Member Costs in an Employed Population	11
EE565 Health Economic Evaluations on Dengue Vaccine in Indonesia	11
EE31 Identifying Equity-Relevant Subgroup Effects in Alzheimer’s Disease: A Literature Review to Support a Distributional Cost-Effectiveness Analysis	11
SA56 Treatment Patterns of Advanced Egfr-Positive Non-Small Cell Lung Cancer (NSCLC) in Latin America	11
PT41 Real-World Evidence in Rare Diseases in France: Treatment Patterns, Healthcare Resource Use, and Related Costs in Von Willebrand Disease (FORvWARD Study)	11
EE705 The Healthcare Resource Utilisation and Associated Costs for Patients with Newly Diagnosed Fragile X Syndrome	11
RWD151 Evaluation of the Effect of Methodological Assumptions on Estimates of Adherence to Antipsychotics: A Real-World Data Study	11
HSD113 Access to Medicines, Care, and Services for Multiple Sclerosis Patients in Central and Eastern European Countries: A Comparative Analysis	11
RWD4 Socioeconomic Burden of Obesity – Increased Rate and Duration of Sick Leave in Patients Living with Obesity: A Cross-Sectional Claims Data Analysis in Germany	11
PCR87 Impact of Signs and Symptoms of Chronic Refractory Gout on Patient Health-Related Quality of Life	11
EE168 Budget Impact Analysis of Adopting Lanreotide in the Treatment of Acromegaly and GEP-NET at Public Hospitals in Saudi Arabia	11
Copyright/Subscription	11
EE340 Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation in a Developing Country	11
EE29 Cost-Effectiveness Analysis and Budgetary Impact of Telescopic Rods for Treatment of Fractures and Correction of Bone Deformities in Children with Osteogenesis Imperfecta in the Brazilian Public	11
EE549 Burden of Disease of Chronic Kidney Disease (CKD) in Type 2 Diabetes (T2D) Using the Standard of Care in Peru	11
EE151 Cost-Minimization of Lorlatinib Versus Alectinib for First Line Treatment for Treatment of Alk-Positive Non–Small-Cell Lung Cancer from the Brazilian Private Healthcare System Perspective	11
EE554 Budget Impact Analysis of Intravenous Acetaminophen in Neonates after Esophageal Atresia and Tracheoesophageal Fistula Repair	11
MSR70 Translation, Cross-Cultural Adaptation, and Psychometric Evaluation of the Brief Illness Perception Questionnaire Into Yoruba Language Among Persons With Chronic Low Back Pain	11
EE558 Key Methodological Considerations for Developing Cost-Offset Budget Impact Models for a Range of Medical Technologies and Cost Perspectives in Ophthalmology	11
EE321 Cost Impact of Next Generation Sequencing Testing in NSCLC with and without RNA Sequencing	11
EE156 Budget Impact Analysis of Inotuzumab Ozogamicin for the Treatment of Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia in Colombia	11
EE27 Risk, Use, and Cost of Infection-Related Hospitalization of Individuals With Alzheimer’s Disease or Dementia	11
HTA88 Reimbursement of CAR-T Cell Therapies in Europe: Key Challenges from Precedents and Lessons for Future	11
MSR82 Combating Sample Scarcity: A Novel Bayesian Approach to Pediatric Basket Trials	10
CO50 Imminent Recurrent Fracture Risk in Patients with Osteoporotic Fractures: A Nationwide Cohort Study in South Korea	10
EE553 An Exploratory Study Assessing the Utility Impact in Second Informal Carers of Patients With Epidermolysis Bullosa	10
EE573 Economic Burden of Chronic Kidney Disease with Type 2 Diabetes in Turkiye	10
EE77 The Cost-Effectiveness of Tradition Chinese Medicine Icaritin Versus Cinobufotalin in Patients with Unresectable Advanced Hepatocellular Carcinoma in China	10
CO56 Radiographic Progression Free Survival as a Surrogate Endpoint for Overall Survival Among Men With Metastatic Castration-Resistant Prostate Cancer	10
MSR84 Summarizing Adverse Event Data in the Absence of High-Level Evidence: The Case of Hearing Implants	10
EE63 Cost-Effectiveness of Olaparib Plus Bevacizumab First-Line Maintenance in Ovarian Cancer Alongside the PAOLA-1 Trial	10
EE67 Insurer and Patient Costs for Repeat Breast Surgery After Initial Lumpectomy for Breast Cancer	10
HTA30 Behavioural Structured Expert Elicitation: A Case Study to Inform Hospitalisation Due to Respiratory Syncytial Virus in the UK	10
EPH184 The Relevance of Insomnia in Relation to Other High-Impact Pathologies. a Systematic Literature Review	10
EE87 Liquid Metformin for Pediatric Patients with Metabolic Syndrome at Risk of Developing DMT2: Cost-Effectiveness Analysis in Mexican Public Health Institutions	10
EPH255 Healthcare Resource Consumption of Patients with Cardiovascular Events after Exacerbations of Chronic Obstructive Pulmonary Disease in Italy: Results from the EXACOS-CV Study	10
HSD124 Treatment Patterns in Pediatric Patients with Atopic Dermatitis	10
EE555 Economic Burden of Cardiorespiratory Hospitalizations Associated With RSV Among US Adults, 2017-2019	10
EE576 Costs Saving Generated by Anti-TNF Biosimilars Market Penetration in France: An Analysis Based on French Health Insurance Open Data	10
EE444 Cost-Effectiveness Analysis of Replacing PCV13 with PCV15 in the Pediatric National Immunization Program of Greece	10
EE448 Exploring Non-Patient Utilities Using Time Trade-Off Exercises in the UK General Population	10
EE85 Cost-Effectiveness Analysis of GAAD Algorithm on the Detection of Early-Stage Hepatocellular Carcinoma in Patients With Chronic Liver Disease in China	9
MSR40 A Comparison of the Performance of a Range of Trial-Level Surrogacy Methods	9
EE476 Budget Impact Analysis of iGlarLixi for Treatment of T2DM in Algerian Setting	9
EE667 The Opportunity of High-Dose Vaccination Against Influenza for Adults Aged 60 and Above in the Netherlands	9
EE402 Social and Economic Burden of Breast Cancer in Russia	9
HTA184 Investigating How Orphan Drug Manufacturers Can Optimize Clinical Trial Design so Patients across Geographies Can Access Life-Saving Innovations	9
HTA188 Does Size Matter? Impact of Population Size on Evidence Quality and Negotiation Outcome for Orphan Drugs in Germany	9
HTA109 Diagnostic Accuracy of 0.3T MRI for Knee Injuries- A Systematic Review	9
EE172 The Wisdom Self-Management Intervention: A Cost-Effectiveness Analysis to Support the Transformation of Type 2 Diabetes Care in England	9
PCR137 A Psycho-Onco Emotional Anxiety (POEM) Framework and Application to Understanding Emotional and Psychological Burden of Living with Cancer	9
EPH142 The Burden of Metastatic or Inoperable HER2+ Breast Cancer on the Italian Health System	9
HPR25 Patient Organisations' Submissions to the Pharmaceutical Pricing Board in Finland	9
EE15 Cost-Consequence Analysis of Ofatumumab in Comparison With Other Disease-Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada	9
HPR17 Changing Landscape of Orphan Drug Reimbursement - Evidence From EU-4 and England	9
EE458 Benefits, Costs and Cost Effectiveness of a Chronic Heart Failure Disease Management Program for Austria – a Decision-Analytic Modeling Study	9
EE633 Analysis of Cost-Effectiveness in Switzerland for a New Implantable Device to Treat Chronic Gastroesophageal Reflux Disease	9
EPH177 Assessing Student Pharmacists’ Knowledge and Perceptions of Electronic Nicotine Delivery Systems (ENDS) – A Cross Sectional Study at One College of Pharmacy	9
HTA98 Distribution of the Positive Added Medical Benefit According to the Early Access Status and the Potential Public Health Interest– Analysis of the French HTA Body Opinions (HAS Transparency Commi	9
EPH168 Assessment of the Prevalence of Emotional Burnout Among Medical Workers in the Republic of Kazakhstan	9
EE506 Budget Impact Analysis of Dapagliflozin in the Treatment of Chronic Kidney Disease in Mexico	9
CO83 Reduction of Transfusion Requirements and Length of Hospital Stay in Patients Undergoing Major Planned Surgery After the Implementation of Patient Blood Management (PBM) in Spain	9
HTA154 Comparing Non-Oncological Rare Condition Submissions to the National Institute for Health and Care Excellence (NICE) Versus Scottish Medicines Consortium (SMC) From 2001 to 2021	9
RWD99 The Financial Burden of DM on the Public Health System of Greece: Using Big Data From Greece	9
EE429 Cost-Effectiveness and Budget Impact Analyses of Enzalutamide for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer in Mexico	9
HSD62 An Analysis of the Status of Newborn Screening Programmes in the European Union and Its Upcoming Developments: What Does This Mean for New Drugs?	9
EE459 Early Intensification of Oral Semaglutide in the UK: A Cost-Effectiveness Analysis Versus Continuing Metformin and SGLT-2 Inhibitor Therapy	9
HTA196 Influence of REvalMED Pilot Program on Drug Evaluations in Spain: An Analysis of Therapeutic Positioning Reports	9
PCR75 Comparing Choice Share Prediction Methods for Discrete Choice Experiments: A Case Study With Hypomethylating Agents in Myelodysplastic Syndromes	9
EE332 Cost-Effectiveness Analysis of Using a Smartphone Application to Improve Timely Vaccination Among Children in the Zaatari Refugees Camp, Jordan	9
HPR50 Challenges That EUnetHTA21 Will Have to Address to Make a Success of Joint Clinical Assessments	9
PCR222 The Value of No Cancer Signal Detected Results from Multi-Cancer Early Detection Tests–Perspectives of People in the General Population	8
EE266 A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients With Iron Deficiency Anemia in China	8
RWD55 Predicting Metastatic Disease Progression in Prostate Cancer Patients Using Machine Learning of PSA Kinetics	8
EE442 Direct Expenses Study of Liver Transplantation Treatment	8
PCR216 Insights from Social Media Posts on the Lived Experience of Alzheimer's Disease	8
EE453 Baseline Cognitive Performance Is a Determinant of Prospective Health Resource Utilization Among Adults with Chronic Stroke: A Secondary Analysis	8
HPR102 Exploring the Cost of Managing Diabetes in Nepal: A Cross-Sectional Analysis of Oral Hypoglycemic Medications	8
RWD53 Assessing the Association of Various Characteristics with Perceived Health Status Among Adults with Skin Cancer in the United States	8
PCR205 Assessment of Healthcare Resource Utilization in Patients with Exocrine Pancreatic Insufficiency in the Pact-CP Registry	8
EPH244 Late-Stage Cancer Diagnosis and Systemic Therapy in England Since 2018	8
MSR15 Psychometric Validation of the Electronic Hidradenitis Suppurativa (HS) Symptom Daily Diary (eHSSDD) and Electronic HS Symptom Questionnaire (eHSSQ) Using Data from the Phase 3 BE HEARD Trials o	8